Exelixis preclinical data

Researchers at the University of California, San Francisco, Pfizer Inc. (NYSE:PFE, New York, N.Y.) and Exelixis reported data from mouse models of pancreatic cancer showing that simultaneous inhibition of c-Met and VEGF signaling reduced tumor invasiveness and metastasis, whereas inhibiting VEGF signaling alone increased invasion and metastasis of tumors. Specifically, mice with pancreatic neuroendocrine tumors that were treated with a neutralizing anti-VEGF antibody or sunitinib had a reduction in tumor burden but also experienced an increase in tumor hypoxia, c-Met activation, and invasion and metastasis. However, concurrent inhibition of c-Met and VEGF signaling with PF-04217903 plus sunitinib with cabozantinib slowed tumor growth while also reducing tumor invasiveness and metastasis. Additionally, median survival times for mice receiving vehicle, PF-04217903 alone, anti-VEGF therapy alone, anti-VEGF therapy plus PF-04217903, and cabozantinib were 14.7, 16.1, 16.4, 17.3 and >20 weeks, respectively. Data were published in Cancer Discovery. ...